Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Myelodysplastic Syndrome Harboring Trisomy 8 |
| |
| Authors: | Takaaki Konuma Yasushi Miyazaki Naoyuki Uchida Kazuteru Ohashi Tadakazu Kondo Hirohisa Nakamae Satoshi Takahashi Takehiko Mori Yukiyasu Ozawa Chiaki Kato Koji Iwato Takahiro Fukuda Tatsuo Ichinohe Yoshiko Atsuta Ken Ishiyama |
| |
| Affiliation: | 1. Department of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan;2. Department of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan;3. Department of Hematology, Toranomon Hospital, Tokyo, Japan;4. Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan;5. Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan;6. Hematology, Graduate School of Medicine, Osaka City University, Osaka, Japan;7. Division of Molecular Therapy, The Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan;8. Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan;9. Department of Hematology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan;10. Department of Hematology, Meitetsu Hospital, Nagoya, Japan;11. Department of Hematology, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Hiroshima, Japan;12. Department of Hematopoietic Stem Cell Transplantation Division, National Cancer Center Hospital, Tokyo, Japan;13. Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan;14. Japanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan;15. Department of Healthcare Administration, Nagoya University Graduate School of Medicine, Nagoya, Japan;16. Department of Hematology, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan |
| |
| Abstract: | Trisomy 8 (+8) is 1 of the most common cytogenetic abnormalities in adult patients with myelodysplastic syndrome (MDS). However, the outcome of allogeneic hematopoietic stem cell transplantation (HSCT) in adult patients with MDS harboring +8 remains unclear. To evaluate the outcome and prognostic factors in patients with MDS harboring +8 as the sole cytogenetic abnormality or in association with other abnormalities, we retrospectively analyzed the Japanese registration data of 381 adult patients with MDS harboring +8 treated with allogeneic HSCT between 1990 and 2013. With a median follow-up period of 53 months, the probability of overall survival and cumulative incidence of relapse at 4 years were 51% and 22%, respectively. In the multivariate analysis, age > 50 years, 2 or more additional cytogenetic abnormalities, and a high risk at the time of HSCT according to the FAB/WHO classification were significantly associated with a higher overall mortality. Nevertheless, no significant impact of the outcome was observed in patients with 1 cytogenetic abnormality in addition to +8. Although 221 patients (58%) had advanced MDS at the time of HSCT, allogeneic HSCT offered a curative option for adult patients with MDS harboring +8. |
| |
| Keywords: | Trisomy 8 Myelodysplastic syndrome Allogeneic hematopoietic stem cell transplantation Cytogenetics Additional abnormality |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
